News

FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca
Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.
PharmExec1d
FDA Approves Expanded Indication for Moderna’s Respiratory Syncytial Virus Vaccine mRESVIA
RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...
STAT5d
Merck’s RSV antibody treatment for infants is approved by FDA
The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.
WXYZ3d
FDA Approves Merck’s Enflonsia to prevent RSV in infants
The Food and Drug Administration has approved a new drug from Merck designed to protect infants ... their mothers did not receive a maternal RSV vaccine.